Chapter 1. Introduction


1.1. Report description and scope

1.2. Research scope

1.3. Research methodology


1.3.1. Market research process

1.3.2. Market research methodology

Chapter 2. Executive Summary


2.1. Global therapeutic vaccines market, 2016 2022 (USD Billion)

2.2. Global therapeutic vaccines market : Snapshot

Chapter 3. Therapeutic Vaccines Market Dynamics


3.1. Introduction

3.2. Market drivers


3.2.1. Global therapeutic vaccines market drivers: Impact analysis

3.2.2. Growing incidences of chronic diseases

3.2.3. Technological advancements

3.3. Market restraints


3.3.1. Global therapeutic vaccines market restraints: Impact analysis

3.3.2. High treatment cost

3.4. Opportunities


3.4.1. Increasing focus on personalized medicine

3.5. Porters five forces analysis


3.5.1. Bargaining power of suppliers

3.5.2. Bargaining power of buyers

3.5.3. Threat from new entrants

3.5.4. Threat from new substitutes

3.5.5. Degree of competition

3.6. Market attractiveness analysis


3.6.1. Market attractiveness analysis, by product segment

3.6.2. Market attractiveness analysis, by technology segment

3.6.3. Market attractiveness analysis, by regional segment

Chapter 4. Global Therapeutic Vaccines Market Competitive Landscape


4.1. Company Market Share Analysis


4.1.1. Global therapeutic vaccines market: company market share, 2015

4.2. Strategic Development


4.2.1. Acquisitions Mergers

4.2.2. New Therapy Launch

4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures

4.2.4. Research and Development, Therapy and Regional Expansion

Chapter 5. Global Therapeutic Vaccines Market Product Segment Analysis


5.1. Global therapeutic vaccines market: Product overview


5.1.1. Global therapeutic vaccines market revenue share, by product, 2014 and 2022

5.2. Addiction Vaccines


5.2.1. Global addiction vaccines market , 2014 2022(USD Billion)

5.3. Autoimmune Disease Vaccines


5.3.1. Global autoimmune disease vaccines market , 2014 2022(USD Billion)

5.4. Infectious Disease Vaccines


5.4.1. Global infectious disease vaccines market , 2014 2022(USD Billion)

5.5. Neurological Disease Vaccines


5.5.1. Global neurological disease vaccines market , 2014 2022(USD Billion)

Chapter 6. Global Therapeutic vaccines Market Technology Segment Analysis


6.1. Global therapeutic vaccines market: Technology overview


6.1.1. Global therapeutic vaccines market revenue share, by technology, 2016 and 2022

6.2. Autologous vaccines


6.2.1. Global therapeutic vaccines market for autologous vaccines, 2014 2022 (USD Billion)

6.3. Allogeneic Vaccines


6.3.1. Global therapeutic vaccines market for allogeneic vaccines, 2014 2022(USD Billion)

Chapter 7. Global Therapeutic vaccines Market Regional Segment Analysis


7.1. Global therapeutic vaccines market: Regional overview


7.1.1. Global therapeutic vaccines market revenue share, by region, 2016 and 2022

7.2. North America


7.2.1. North America therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)

7.2.2. North America therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)

7.2.3. U.S.


7.2.3.1. U.S. therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)

7.2.3.2. U.S. therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)

7.3. Europe


7.3.1. Europe therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)

7.3.2. Europe therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)

7.3.3. Germany


7.3.3.1. Germany therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)

7.3.3.2. Germany therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)

7.3.4. France


7.3.4.1. France therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)

7.3.4.2. France therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)

7.3.5. UK


7.3.5.1. UK therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)

7.3.5.2. UK therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)

7.4. Asia Pacific


7.4.1. Asia Pacific therapeutic vaccines market revenue, by product, 2014 2022, (USD Billion)

7.4.2. Asia Pacific therapeutic vaccines market revenue, by technology, 2014 2022, (USD Billion)

7.4.3. China


7.4.3.1. China therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)

7.4.3.2. China therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)

7.4.4. Japan


7.4.4.1. Japan therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)

7.4.4.2. Japan therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)

7.4.5. India


7.4.5.1. India therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)

7.4.5.2. India therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)

7.5. Latin America


7.5.1. Latin America therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)

7.5.2. Latin America therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)

7.5.3. Brazil


7.5.3.1. Brazil therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)

7.5.3.2. Brazil therapeutic vaccines market revenue, by technology, 2014 2022 (USD Billion)

7.6. Middle East and Africa


7.6.1. Middle East and Africa therapeutic vaccines market revenue, by product, 2014 2022 (USD Billion)

7.6.2. Middle East and Africa therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)

Chapter 8. Company Profile


8.1. Valeant Pharmaceuticals


8.1.1. Overview

8.1.2. Financials

8.1.3. Therapy portfolio

8.1.4. Business strategy

8.1.5. Recent developments

8.2. Agenus Inc.


8.2.1. Overview

8.2.2. Financials

8.2.3. Therapy portfolio

8.2.4. Business strategy

8.2.5. Recent developments

8.3. GlaxoSmithKline plc.


8.3.1. Overview

8.3.2. Financials

8.3.3. Therapy portfolio

8.3.4. Business strategy

8.3.5. Recent developments

8.4. Immunocellular Therapeutics, Ltd.


8.4.1. Overview

8.4.2. Financials

8.4.3. Therapy portfolio

8.4.4. Business strategy

8.4.5. Recent developments

8.5. Pfizer Inc.


8.5.1. Overview

8.5.2. Financials

8.5.3. Therapy portfolio

8.5.4. Business strategy

8.5.5. Recent developments

8.6. Novartis AG


8.6.1. Overview

8.6.2. Financials

8.6.3. Therapy portfolio

8.6.4. Business strategy

8.6.5. Recent developments

8.7. Argos Therapeutics


8.7.1. Overview

8.7.2. Financials

8.7.3. Therapy portfolio

8.7.4. Business strategy

8.7.5. Recent developments

8.8. Bavarian Nordic


8.8.1. Overview

8.8.2. Financials

8.8.3. Therapy portfolio

8.8.4. Business strategy

8.8.5. Recent developments

8.9. Galena Biopharma


8.9.1. Overview

8.9.2. Financials

8.9.3. Therapy portfolio

8.9.4. Business strategy

8.9.5. Recent developments

8.10. Transgene


8.10.1. Overview

8.10.2. Financials

8.10.3. Therapy portfolio

8.10.4. Business strategy

8.10.5. Recent developments

8.11. Vaccinogen, Inc.


8.11.1. Overview

8.11.2. Financials

8.11.3. Therapy portfolio

8.11.4. Business strategy

8.11.5. Recent developments